A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease
2 other identifiers
interventional
160
1 country
5
Brief Summary
The investigational product is a specially formulated TCM and administered in the form of a capsule. Basic pre-clinical studies have suggested that it may have good immunomodulating functions, increases the activities of T-cells, B-cells and NK cells, enhances mitochondrial antioxidant status on various tissues including brain tissues. Therefore, this formulation may have special values in improving symptoms in Parkinson's disease patients. The purpose of the study is to determine the efficacy and safety of ViNeuro in patients with Parkinson's disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable parkinson-disease
Started Oct 2005
Typical duration for not_applicable parkinson-disease
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2005
CompletedFirst Submitted
Initial submission to the registry
August 15, 2007
CompletedFirst Posted
Study publicly available on registry
August 17, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2008
CompletedSeptember 5, 2013
July 1, 2013
August 15, 2007
September 3, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The primary efficacy outcome is the change from baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) (Appendix 6) Parts II and III total scores at the end of 24 weeks. The UPDRS is to be performed one hour after L-dopa treatment.
24 Weeks
Secondary Outcomes (3)
Change from baseline in the individual Part II and Part III total scores, sum of Parts I-III total scores, Part IV total score of the UPDRS at each follow-up visit...
24 weeks
Change from baseline in the number of "off" hours throughout the study at each follow-up visit.
The mean number of daily "off" hours over the last 7 days before each study visit, except for the screening visit, will be used for the analysis.
Change from baseline in the total daily dose in patients who received concomitant levodopa therapy throughout the study at each follow-up visit; Change from baseline in Red Cell Superoxide Dismutase Activity at 24 week.
24 weeks
Interventions
Eligibility Criteria
You may qualify if:
- A subject will be eligible for study participation if he/she meets all the following criteria:
- Age of at least 30 years
- Diagnosis of symptomatic, idiopathic Parkinson' disease using The United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria (Appendix 3 in the protocol)
- Stage 1-4 on the modified Hoehn and Yahr scale (Appendix 4 in the protocol)
- Possesses three of the four cardinal signs of Parkinson's disease, i.e. rigidity, bradykinesia, resting tremor and postural instability, without any other known or suspected cause for their parkinsonism
- If receiving levodopa or other symptomatic treatments, the subject should have shown a good response to it and have been on a stable dosage for at least 1 month prior to study entry
- Voluntarily signs and dates an Informed Consent Form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to any study-specific procedures.
You may not qualify if:
- A subject will be excluded from the study if he/she meets any of the following criteria:
- Presence of atypical parkinsonian syndromes
- Dementia as defined by the Mini-Mental State Examination score (Appendix 5 in the protocol) of 22 or less
- Serious concurrent illness, such as active cardiac, renal, liver, or neoplastic disease
- Used centrally active therapies, e.g. hypnotics, antidepressants, anxiolytics, within 60 days before study entry
- Used methylphenidate, cinnarizine, reserpine, amphetamine, or monoamine oxidase-A inhibitors, e.g. pargyline, phenelzine, or tranylcpromine, within 3 months of study entry
- Has history of receiving any neuroleptics
- Used alpha-methyldopa or flunarizine within 6 months of study entry
- Females who are pregnant or breastfeeding.
- Subjects who are currently participating in another investigational study or has been taking any investigational drug within the last 4 weeks prior to screening of this study (Visit 1).
- Subjects who are taking any traditional Chinese medication, or has been taking any traditional Chinese medication within the last 2 weeks prior to screening of this study (Visit 1).
- Any criteria, which, in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hospital Authority, Hong Konglead
- Vigconic (International) Ltd.collaborator
Study Sites (5)
Prince of Wales Hospital
Hong Kong, China
Princess Margaret Hospital
Hong Kong, China
Queen Elizabeth Hospital
Hong Kong, China
Tseung Kwan O Hospital
Hong Kong, China
United Christian Hospital
Hong Kong, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jonas HM Yeung, Dr
Department of Medicine and Therapeutics, Prince of Wales Hospital/ The Chinese University of Hong Kong
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
August 15, 2007
First Posted
August 17, 2007
Study Start
October 1, 2005
Study Completion
September 1, 2008
Last Updated
September 5, 2013
Record last verified: 2013-07